Sarah Murawski, MPAS, discusses how telemedicine can impact the use of chimeric antigen receptor T-cell therapy in patients with cancer at the Association of Community Cancer Centers National Oncology Conference.
Sarah Murawski, MPAS, physician assistant in Medicine at the Vanderbilt University Medical Center, discusses how telemedicine can impact the use of chimeric antigen receptor (CAR) T-cell therapy in patients with cancer at the Association of Community Cancer Centers (ACCC) National Oncology Conference.
CAR T-cell therapy is still new. Murawski says we don’t know a lot about these agents, but telemedicine will be essential and provide more patients with access to this treatment. Currently, CAR T-cell therapy is not offered at every institution.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More